TH79809A - Anti-thrombotic therapy of autoimmune disease in patients who were not successful in previous therapy. - Google Patents
Anti-thrombotic therapy of autoimmune disease in patients who were not successful in previous therapy.Info
- Publication number
- TH79809A TH79809A TH501005957A TH0501005957A TH79809A TH 79809 A TH79809 A TH 79809A TH 501005957 A TH501005957 A TH 501005957A TH 0501005957 A TH0501005957 A TH 0501005957A TH 79809 A TH79809 A TH 79809A
- Authority
- TH
- Thailand
- Prior art keywords
- therapy
- patients
- autoimmune disease
- successful
- antagonist
- Prior art date
Links
- 206010003816 Autoimmune disease Diseases 0.000 title claims abstract 4
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 title claims abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 4
- 230000002785 anti-thrombosis Effects 0.000 title 1
- 239000003146 anticoagulant agent Substances 0.000 title 1
- 230000003042 antagnostic Effects 0.000 claims abstract 7
- 239000005557 antagonist Substances 0.000 claims abstract 7
- 102000004965 antibodies Human genes 0.000 claims abstract 4
- 108090001123 antibodies Proteins 0.000 claims abstract 4
- 230000002792 vascular Effects 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drugs Drugs 0.000 claims abstract 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 238000001050 pharmacotherapy Methods 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 abstract 2
Abstract
DC60 (15/03/49) แบบยื่นขอนี้อธิบายการรักษาด้วยแอนทาโกนิสท์ของการเจริญเติบโตของเส้นเลือด เช่น แอนตี้-VEGF แอนตี้บอดี้ โดยเฉพาะอย่างยิ่ง, แบบยื่นขอนี้อธิบายการใช้ของแอนทาโกนิสท์ ดังกล่าวเพื่อรักษาโรคที่มีการสร้างภูมิคุ้มกันขึ้นเองในผู้ป่วยซึ่งไม่ประสบความสำเร็จในการรักษาก่อน หน้านี้ด้วย DMARDs หรือตัวยับยั้ง TNFอัลฟา แบบยื่นขอนี้อธิบายการรักษาด้วยแอนทาโกนิสท์ของการเจริญเติบโตของเส้นเลือด เช่น แอนตี้ -VEGF แอนตี้บอดี้ โดยเฉพาะอย่างยิ่ง, แบบยื่นขอนี้อธิบายการใช้ของแอนทาโกนิสท์ ดังกล่าวเพื่อรักษาโรคที่มีการสร้างภูมิคุ้มกันขึ้นเองในผู้ป่วยซึ่งไม่ประสบความสำเร็จในการรักษาก่อน หน้านี้ด้วย DMARDs หรือตัวยับยั้ง TNF อัลฟา สิทธิบัตรยา DC60 (15/03/49) This submission describes antagonist therapy of vascular growth, such as the anti-VEGF anti-body. In particular, this submission describes the use of Ann. Taconist It is said to treat autoimmune disease in patients who had not achieved previous treatment with DMARDs or subjected alpha TNF inhibitors. This describes antagonist therapy. Of vascular growth, such as the anti-VEGF anti-body. In particular, this submission describes the use of antagonist As mentioned above, to treat autoimmune disease in patients who had not been successful in previous treatment with DMARDs or the drug's patent alpha TNF inhibitor.
Claims (4)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH79809B TH79809B (en) | 2006-09-07 |
| TH79809A true TH79809A (en) | 2006-09-07 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0518105A (en) | angiogenesis antagonist use and anti-vegf antibody use | |
| DK2484365T3 (en) | Compositions and Methods for the Treatment of Neovascular Diseases | |
| CY1111703T1 (en) | ANTI-C5 COMPONENT SYSTEM COMPONENTS AND THEIR USE | |
| MA28935B1 (en) | PREPARATION AND USE OF BIPHENYL-4-YL CARBONYLAMINO ACID DERIVATIVES IN THE TREATMENT OF OBESITY | |
| HRP20110334T1 (en) | Tgf beta 1 specific antibodies | |
| MX2009011226A (en) | Pdgfrbeta-specific inhibitors. | |
| EP2826791A3 (en) | Humanized anti-C5aR antibodies | |
| WO2006052723A3 (en) | G protein coupled receptor agonists and antagonists and methods of use | |
| AR079903A1 (en) | FORMULATION OF ANTIBODY AND THERAPEUTIC REGIMES. PHARMACEUTICAL PACKAGING. KIT | |
| WO2005107726A3 (en) | Method for the treatment of back pain | |
| ATE482213T1 (en) | PYRAZOLOÄ1,5-AÜPYRIMIDINES SUITABLE AS INHIBITORS OF PROTEIN KINASES | |
| MA27838A1 (en) | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT WITH INADEQUATE RESPONSE TO A TNF-ALPHA INHIBITOR | |
| HRP20220426T1 (en) | Antigen-binding proteins that activate the leptin receptor | |
| EA201100814A1 (en) | PHARMACEUTICAL FORMS OF APPLICATION CONTAINING NIFEDIPINE OR NIZOLDIPIN AND ANTAGONIST ANGIOTENZINE II AND / OR DIURETIC | |
| DE602006017574D1 (en) | USE AS PROTEIN KINASE INHIBITORS BENZIMIDAZOLE | |
| TH79809A (en) | Anti-thrombotic therapy of autoimmune disease in patients who were not successful in previous therapy. | |
| NO20026286D0 (en) | New peptides | |
| JP2011504736A5 (en) | ||
| TH79809B (en) | Anti-thrombotic therapy of autoimmune disease in patients who were not successful in previous therapy. | |
| WO2006138589A3 (en) | Opioid receptor ligands | |
| WO2005058234A3 (en) | Methods and compositions relating to ccr5 antagonist, ifn-ϝ and il-13 induced inflammation | |
| Pease | CCR1 antagonism for the treatment of inflammatory diseases: Focus on CCX-354 | |
| WO2004009633A8 (en) | Serotonin receptor | |
| DE602004020337D1 (en) | Anticholinergic drugs for the treatment of urinary tract disorders | |
| WO2008073634A3 (en) | Compositions and methods for detecting and treating endothelial dysfunction |